Author name: Leonardo Arias

La financiación como motor del crecimiento empresarial   El crecimiento de muchas startups depende del acceso a financiación externa. Los emprendedores suelen iniciar sus proyectos con recursos propios o apoyo de familiares y amigos. Sin embargo, cuando el negocio comienza a cre …

Center for Biologics Evaluation and Research Director Vinay Prasad will exit the FDA for the second time after a controversial run that saw the oncologist butt heads with colleagues and ruffle feathers in biopharma after presiding over the rejection of several rare disease therapies.

The startup is seeking regulatory approval in Europe and the U.S. for the device, which restored vision to patients with late-stage macular degeneration in a small clinical trial.

The diabetes tech business is now operating as a standalone, public company. Shares began trading on Friday.

The orthopedic firm published data showing patients with its Persona IQ implant had lower revision and physical therapy rates than those who received traditional knee implants.

The Rochester, Minnesota-based nonprofit health system said increases in outpatient, hospital and surgical volumes boosted revenue for the year.

Servier will pick up Ojemda, which received FDA approval in 2024 to treat pediatric glioma. The drug clocked sales of $155 million for Day One Biopharmaceuticals in 2025.

Expecting pivotal data this year, the company has raised a Series C round to support the launch of a noninvasive device designed to treat brain diseases using light and sound. 

Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.

TrumpRX and DTC sales may expand prescription drug access, but they will not solve the affordability crisis by themselves.